Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Open accessAbstract
Current pharmacotherapies for addiction represent opportunities for facilitating treatment and are forming a foundation for evaluating new medications. Furthermore, validated animal models of addiction and a surge in understanding of neurocircuitry and neuropharmacological mechanisms involved in the development and maintenance of addiction - such as the neuroadaptive changes that account for the transition to dependence and the vulnerability to relapse - have provided numerous potential therapeutic targets. Here, we emphasize a 'Rosetta Stone approach', whereby existing pharmacotherapies for addiction are used to validate and improve animal and human laboratory models to identify viable new treatment candidates. This approach will promote translational research and provide a heuristic framework for developing efficient and effective pharmacotherapies for addiction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The field has excellent and validated animal models and well developed clinical models that, combined with neurocircuitry analysis, will provide a unique approach to medication development emphasizing excessive incentive salience, loss of brain reward function, gain of stress function driving negative reinforcement, and dysregulation of executive function, key components driving compulsive drug寻求.
“Our contention is that the field of the neurobiology of addiction has excellent and validated animal models and well developed clinical models that, combined with the neurocircuitry analysis herein, will provide a unique approach to medication development that emphasises excessive incentive salience, the loss of brain reward function, and the gain of stress function that drive negative reinfor”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [185]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 262 · Cited by 154
Research works printed but not linked: 1
- [173]Kornetsky C Bain G Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse 6 Adler MW Cowan A 211 231 Wiley-Liss New York 1990
- Authors
- Koob, G. F., Kenneth Lloyd, G., & Mason, B. J.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Koob, George F.
- ORCID
- Koob, George F.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-06
- Volume
- 8
- Issue
- 6
- Pages
- 500-515
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2760328
- OpenAlex
- W2055949337
- Cited by
- 154
- References
- 262
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 1 · 2020: 4 · 2019: 5 · 2018: 9 · 2017: 13 · 2016: 10 · 2015: 14 · 2014: 18 · 2013: 11 · 2012: 8
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R01AA008459, AA12602, R37AA014028, R01AA014028, AA-06420, AA-08459, P50AA006420, R37AA008459, R01AA012602, P60AA006420)
- National Institute on Drug Abuse (R01DA010072, DA04043, DA04398, DA-10072, R01DA004398, P20DA024194, R01DA004043)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 26741, P01DK026741)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- drug addiction, translational research, animal models of addiction, relapse vulnerability, dependency, therapeutic target
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Nerve Net, Substance-Related Disorders, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
